The U.S. Anxiety Access Report

The clearest way to see access is as a cascade that narrows at each step. The starting point is prevalence. NIMH, drawing on the National Comorbidity Survey Replication, puts the past-year prevalence of any anxiety disorder at 19.1% of US adults, lifetime prevalence at 31.1%, and serious impairment among those affected at 22.8%.

The next step is treatment. Of adults with any anxiety disorder, NCS-R analysis found that 36.9% received any treatment in a given year. The step after that is adequacy. Of the people who received treatment, 33.9% received care that met the survey's definition of minimally adequate, meaning a threshold number of therapy visits or an adequate medication course with follow-up. Carried through the full cascade, only a minority of adults with an anxiety disorder receive care that meets that adequacy threshold.

A second, more recent anchor comes from the CDC Household Pulse Survey, which has reported recent symptoms of anxiety or depression in a substantial share of adults, around 27% in recent waves. Pulse measures symptoms with a short screener rather than diagnoses with a full interview, so its numbers run higher and answer a different question. The two sources are best read side by side, not merged into one figure.

NCS-R remains the canonical disorder-level anchor for US anxiety prevalence, even though its fieldwork dates to 2001 to 2003, because no later national survey has replicated its full diagnostic interview. 'Minimally adequate care' is a specific research definition, not a statement that the care was clinically sufficient for the patient. The Pulse figure and the NCS-R figure measure different things and shouldn't be compared directly.